Iovance Biotherapeutics, a leader in tumor infiltrating lymphocyte (TIL) therapies for cancer, announced its senior leadership will present at the 2026 Jefferies Global Healthcare Conference in London on November 16. The company is known for its FDA-approved TIL therapy Amtagvi, used for advanced melanoma, and is advancing next-generation TIL treatments for various solid tumors. This presentation highlights Iovance's ongoing innovation and commercial progress in cancer cell therapies. The event will be webcast live and available for later viewing on Iovance's investor website.
Iovance Biotherapeutics shares are trading at USD 7.62 on Pluang, down 5.81% in the last day, with a market cap of $3.74 billion. The stock sees a typical hold time of 7 days and current order activity shows 62% buying interest. These figures are as of Nov 13, 2026 04:11 WIB.
Pomerantz LLP is investigating Iovance Biotherapeutics for potential securities fraud following a revision in its Phase 2 lung cancer trial results. Initially reported as "Positive," the data was later described as "Consistent with Previously Reporte...
David H. Lerner focuses on long-term biotech investments using technical analysis, emphasizing price action and volume rather than traditional fundamentals. He targets small-cap biotech companies advancing beyond Phase 2 trials, especially those deve...
